307 related articles for article (PubMed ID: 11967792)
1. Neurohumoral blockade in CHF management.
Willenbrock R; Philipp S; Mitrovic V; Dietz R
J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1 Suppl 1():24-30. PubMed ID: 11967792
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
3. Exploring new treatment strategies in heart failure.
Swedberg K
Blood Press Suppl; 2000; 1():44-8. PubMed ID: 11059637
[TBL] [Abstract][Full Text] [Related]
4. The renin-angiotensin-aldosterone system and heart failure.
Sayer G; Bhat G
Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
[TBL] [Abstract][Full Text] [Related]
5. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.
Kjaer A; Hesse B
Clin Physiol; 2001 Nov; 21(6):661-72. PubMed ID: 11722473
[TBL] [Abstract][Full Text] [Related]
6. Is too much neurohormonal blockade harmful?
Anand IS
Curr Cardiol Rep; 2004 May; 6(3):169-75. PubMed ID: 15075050
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
8. Neurohormonal modulation in heart failure: ACE inhibition and beyond.
Remme WJ
Eur Heart J; 1995 Dec; 16 Suppl N():73-8. PubMed ID: 8682065
[TBL] [Abstract][Full Text] [Related]
9. Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure.
Shinohara H; Fukuda N; Soeki T; Sakabe K; Onose Y; Tamura Y
Heart Vessels; 2002 Dec; 17(2):47-52. PubMed ID: 12541093
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies.
Moser DK; Biddle MJ
Crit Care Nurs Clin North Am; 2003 Dec; 15(4):423-37, vii-viii. PubMed ID: 14717387
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Miller AB; Srivastava P
Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
[TBL] [Abstract][Full Text] [Related]
12. New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure.
Martineau P; Goulet J
Ann Pharmacother; 2001 Jan; 35(1):71-84. PubMed ID: 11197588
[TBL] [Abstract][Full Text] [Related]
13. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Adams KF
Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the survival benefit of neurohormonal antagonists in the management of geriatric congestive heart failure.
Firdaus M; Bukhari N
J Okla State Med Assoc; 2003 Mar; 96(3):133-9. PubMed ID: 12688226
[TBL] [Abstract][Full Text] [Related]
16. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
17. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
Jorde UP
Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
[TBL] [Abstract][Full Text] [Related]
18. Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention.
Bernal J; Pitta SR; Thatai D
Am J Cardiovasc Drugs; 2006; 6(6):373-81. PubMed ID: 17192127
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone antagonists in hypertension and heart failure.
Mantero F; Lucarelli G
Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
